1-6 of 6
Joanne I. Adamkewicz
Close
Sort by
Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 626.
https://doi.org/10.1182/blood-2019-123689
Published: 2019
Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1285.
https://doi.org/10.1182/blood-2019-123961
Published: 2019
Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1907.
https://doi.org/10.1182/blood-2019-123652
Published: 2019
Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Genevive Hernandez, PhD, Ling-Yuh Huw, PhD, Anton Belousov, PhD, Deanna Wilson, MS, Hartmut Koeppen, MD PhD, Ron McCord, PhD, Kun Peng, PhD, Nancy L Bartlett, MD, Lihua E Budde, MD PhD, Sarit Assouline, MD, Loretta J. Nastoupil, MD MSc, Dok Hyun Yoon, MD PhD, Matthew J Matasar, MD, Brendan Bender, PhD, Antonia Kwan, MD PhD MRCPCH, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Shen Yin, PhD, Michael C Wei, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1585.
https://doi.org/10.1182/blood-2019-123933
Published: 2019
Journal Articles

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Michael U. Callaghan, Claude Negrier, Guy Young, Liane Khoo, Johnny Mahlangu, Jerzy Windyga, Johannes Oldenburg, Jin Xu, Olivier Catalani, Elina Asikanius, Joanne I. Adamkewicz, Midori Shima, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3668.
https://doi.org/10.1182/blood.V130.Suppl_1.3668.3668
Published: 2017
Journal Articles

Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Cherie Green, Mark Yan, Stefani Nalle, Connie Ma, Alberto Robert, Judy Zhong, Kartik Krishnan, Patrick Phuong, PharmD, John Byon, Paul Woodard, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD, Joanne I. Adamkewicz, Jeffrey M. Venstrom, Monique Dail
Journal: Blood
Blood (2017) 130 (Supplement 1): 4241.
https://doi.org/10.1182/blood.V130.Suppl_1.4241.4241
Published: 2017